Article

Absolute and Relative Handgrip Strength as Indicators of Self-Reported Physical Function and Quality of Life in Breast Cancer Survivors: The EFICAN Study

Alba Esteban-Simón 1,2,*, David Manuel Díez-Fernández 1,2, Eva Artés-Rodríguez 3, Miguel Ángel Casimiro-Artés 4, Manuel Antonio Rodríguez-Pérez 1,2, Herminia Moreno-Martos 5, Antonio Jesús Casimiro-Andújar 1,2 and Alberto Soriano-Maldonado 1,2

Citation: Esteban-Simón, A.; Díez-Fernández, D.M.; Artés-Rodríguez, E.; Casimiro-Artés, M.A.; Rodríguez-Pérez, M.A.; Moreno-Martos, H.; Casimiro-Andújar, A.J.; Soriano-Maldonado, A. Absolute and Relative Handgrip Strength as Indicators of Self-Reported Physical Function and Quality of Life in Breast Cancer Survivors: The EFICAN Study. Cancers 2021, 13, 5292. https://doi.org/10.3390/cancers13125292

Academic Editor: Charles L. Shapiro

Received: 15 August 2021
Accepted: 19 October 2021
Published: 21 October 2021

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

1 Department of Education, Faculty of Education Sciences, University of Almería, 04120 Almería, Spain; daviddiez@ual.es (D.M.D.-F.); manolo.rodriguez@ual.es (M.A.R.-P.); casimiro@ual.es (A.J.C.-A.); asoriano@ual.es (A.S.-M.)
2 CERNEP Research Centre, SPORT Research Group (CTS-1024), University of Almería, 04120 Almería, Spain; daviddiez@ual.es (D.M.D.-F.); manolo.rodriguez@ual.es (M.A.R.-P.); casimiro@ual.es (A.J.C.-A.); asoriano@ual.es (A.S.-M.)
3 Area of Statistics and Operative Research, Department of Mathematics, Faculty of Sciences, University of Almería, 04120 Almería, Spain; eartes@ual.es
4 Realtrack Systems S. L., 04009 Almería, Spain; miguelcasico@correolealmeria.es
5 Servicio Andaluz de Salud, Unidad de Gestión Clínica Almería Periferia, Distrito Sanitario Almería, 04009 Almería, Spain; herminiam.moreno.sspa@juntadeandalucia.es
* Correspondence: aes167@ual.es or albaestebansimon@gmail.com

Simple Summary: Breast cancer is the most diagnosed type of cancer worldwide and it has a high survival rate. Thus, side effects related to breast cancer and treatments compromise lots of people’s physical functions and health-related quality of life. For this reason, it is important to manage these side effects in the follow up after treatments. The handgrip strength and the handgrip strength relative to body mass index may constitute useful, simple, quick and economically feasible tools that may help clinicians detecting these side effects, which is key to undertake actions for improving the physical function and health-related quality of life of breast cancer survivors.

Abstract: Background: Although breast cancer (BC) is the most prevalent type of cancer in the world, its high survival rate implies that many people live long after the treatments and face their side effects. The physical function (PF) and health-related quality of life (HRQoL) of people surviving BC decreases significantly, which makes important to identify markers that may be associated with a better health status and prognosis. Previous studies suggest that handgrip strength (HGS) and HGS relative to the body mass index (rHGS) are good indicators of PF and HRQoL in different populations. However, it is unknown whether this applies to BC survivors. This study aimed to evaluate the association of HGS and rHGS with PF and HRQoL in this population. Methods: Sixty female BC survivors participated. Handgrip strength was assessed with a dynamometer. Arm volume was estimated and upper limb impairments, as well as cancer-related fatigue, depression, life satisfaction and HRQoL, were assessed using standardized questionnaires. Results: Higher levels of HGS and rHGS were associated with higher levels of HRQoL, lower cancer-related fatigue, and fewer problems with the affected arm. Conclusions: These results suggest that HGS may be a good indicator of self-reported PF and HRQoL in female BC survivors.

Keywords: cancer; physical fitness; muscular strength; disability; life satisfaction; depression
1. Introduction

Breast cancer has the highest incidence worldwide with more than 2.2 million new diagnoses in 2020 [1]. In Europe, there were 531,086 new diagnoses during 2020 [1]. According to the Spanish Association against Cancer (AECC) [2], 33,307 new cases were diagnosed during 2019. Nevertheless, ongoing advances in early detection and treatment of breast cancer have led to a significant mortality reduction. Breast cancer is the type of cancer with the highest survival rate following diagnosis, with 86% of patients surviving after 5-year [3]. Such a high survival rate leads to more people living with the side effects of the disease and its core treatments (chemotherapy, surgery, and radiotherapy) [4]. These side effects include the presence of lymphedema [5], cancer-related fatigue [6], shoulder–arm disabilities [7,8], lower levels of cardiorespiratory fitness [9,10] and muscular strength [11,12], sarcopenia [13], cardiac toxicity [14] or depression [15], among others. This implies a considerable decrease in patients’ health-related quality of life (HRQoL) [16], and could imply more difficulties to perform basic daily life tasks, such as dressing, combing hair, working, shopping, exercising, etc.

Muscular strength is a powerful marker of present and future health in children [17], adolescents [18,19], adults [20] and older adults [21]. In general population, higher levels of muscle strength have shown to be related to a lower risk of developing cardiovascular disease [22], type 2 diabetes [20], fragility [23] and mortality [24]. Specifically, handgrip strength (HGS), and HGS relative to the body mass index (BMI), have been proposed as highly relevant health indicators in different populations, such as young and older adults [25], adult males [26], aging adults [27], women with systemic lupus erythematosus [28], and women with fibromyalgia [29]. HGS and relative HGS (rHGS) have also been proposed as a cardiometabolic risk predictor in children and adolescents [30] and in middle-aged and older people [31,32], and as an all-cause [33–35] and cancer [36] mortality predictor, allowing to obtain useful information from a simple, quick, and very low-cost assessment.

The relationship of HGS with physical function and HRQoL in female breast cancer survivors has been studied. Higher HGS was associated with less treatment-related disability [37], less fear when using the affected limb in addition to less perceived weakness and less pain in the affected arm [38], greater activity of the upper limbs [38], reduced presence of depressive symptoms [39,40], higher self-reported HRQoL [41,42], less cancer-related fatigue [43,44] and a more favorable body composition [45]. However, information on the association of rHGS with health-related outcomes including HRQoL and cancer-associated side effects is scarce in female breast cancer survivors. rHGS is a good indicator of general health in different populations. For instance, higher levels of rHGS are associated with greater mobility in older adults [46,47], better cardiovascular health in obese women [48], lower prevalence of metabolic syndrome in adults [49], lower prevalence of osteoporosis in women [50], lower cardiometabolic risk in women with systemic lupus erythematosus [28], and lower risk of depressive mood in women [39]. Therefore, we speculated that higher rHGS would be related to better self-reported physical function and HRQoL in female breast cancer survivors.

Consequently, the aim of this study was to assess the association of HGS and rHGS with physical function and HRQoL in female breast cancer survivors. Additionally, the secondary aim was to explore if the association of HGS and rHGS of the affected and non-affected arm with all the outcomes differed.

2. Materials and Methods

2.1. Design

A cross-sectional study was conducted with the baseline values of the EFICAN (Ejercicio Físico para pacientes con CÁNcer de mama) clinical trial [51].
2.2. Participants

Sixty women voluntarily participated in this study. They were recruited through different cancer-related associations and through announcements on social networks, press and radio in the city of Almeria. The inclusion criteria were to be a breast cancer survivor and to have completed the core treatments of the disease (consisting of adjuvant chemotherapy, surgery and/or radiotherapy) in the 10 years prior to the beginning of the study. The exclusion criteria were the existence of pulmonary or cardiovascular disease, having metastatic breast cancer, planning a breast reconstruction intervention within 3 months of the beginning of the study and regularly performing >300 min per week of structured exercise. The study protocol was approved by the Ethics Committee of the Hospital Universitario Torrecárdenas de Almeria, Spain (ref: Ejercicio-CáncerUAL [98/2019]). In addition, all the participants were duly informed and signed the informed consent form prior to being included in the study.

2.3. Protocol

Women interested in participating in the study filled out an online questionnaire asking for information about their disease and treatment. Participants who met the inclusion criteria underwent a medical evaluation to confirm that they met the study participation criteria. After obtaining medical authorization to participate in the study, the participants underwent a physical assessment at the University of Almeria facilities. These assessments began by completing a series of questionnaires related to different quality of life variables. Then, the presence of lymphedema and handgrip strength were assessed.

2.4. Assessments

2.4.1. Handgrip Strength

Handgrip strength was assessed using a digital dynamometer (TKK 5401 Grip-D, Takei Scientific Instruments Co. Ltd., Niigata, Japan), which has been used in previous studies on female breast cancer survivors [38,52–54]. Two attempts were made, alternating each hand, and the best result from each was selected. The mean value obtained was taken as the total score [55].

Handgrip strength relative to BMI was defined as HGS divided by BMI [46].

2.4.2. Shoulder–arm Disabilities

To assess shoulder–arm disabilities, we studied the arm volume (which is related to lymphedema) and the participants’ disability or difficulty in the upper limbs.

The arm volume was assessed by estimating the volume of each arm using the truncated cone formula [56]:

\[ V = \frac{1}{12\pi} \sum_{i=1}^{n} L(C_i^2 + C_iC_{i-1} + C_{i-1}^2) \]

where \( n \) = number of segments, \( L \) = length of each segment, and \( C_i \) and \( C_{i-1} \) = circumference at each end of the segment.

For this, the arm’s perimeter was measured at 6 different points (with 6 cm of separation between them) depending on the length of each participant’s arms following the protocol by Sander et al. [56] The difference of volume between arms were computed.

Upper-limb disability or difficulty was assessed using the Spanish version [57] of the Disabilities of the Arm, Shoulder, and Hand (DASH) questionnaire [57] with one optional additional module, intended to measure the extent of the injury to the upper limb when working. The final score ranged 0 to 100, where a higher number indicated greater disability or difficulties.
2.4.3. Cancer-Related Fatigue

Cancer-related fatigue was measured using the Spanish version [58] of the Functional Assessment of Cancer Therapy-Fatigue (FACT-F) questionnaire [59]. The scores range from 0 to 52, where a higher score indicates lower fatigue.

2.4.4. Depression

Depressive symptoms were assessed using the Spanish version [60] of the 20-item Center for Epidemiologic Studies-Depression Scale (CES-D) questionnaire [61]. The final score ranges from 0 to 60. A higher the total score means greater depressive symptoms.

2.4.5. Life Satisfaction

Life satisfaction was assessed through the Satisfaction With Life Scale (SWLS) questionnaire [62], using its Spanish version [63], which has been validated for cancer patients [64]. The final score ranges from 0 to 25, where a greater score indicates greater satisfaction with life.

2.4.6. Health-Related Quality of Life

HRQoL was assessed using the European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire-Core30 (EORTC QLQ-C30) [65] in its Spanish version [66], with its complementary module for breast cancer European Organization for Research and Treatment of Breast Cancer, Cancer-Specific Quality-of-Life Questionnaire Module (EORTC QLQ-BR23) [67], also in its Spanish version [68]. Each of the subscale has a total score of 1–100, obtained as explained elsewhere [69], a higher score means a higher response level.

2.5. Statistical Analysis

Descriptive characteristics are presented in Table 1, using the mean and standard deviation for quantitative variables, and the number and frequency for categorical variables. The normality of the main variables was studied using histograms, Q-Q plots and through the Kolmogorov–Smirnov test. The association of HGS and rHGS with the aforementioned outcome variables was analyzed through partial correlation, adjusting for age, BMI and time since the disease diagnosis, to control for potential confounding. Finally, a linear regression analysis was performed including the variables related to physical function and quality of life as dependent variables in separate models, and the HGS as the independent variable, using the same adjustment variables. Homoscedasticity and linearity assumptions of the linear regression models, as well as the normality, no-multicollinearity and no-autocorrelation of the residuals were checked. In addition, the detection of possible outliers was studied through boxplots. Additional exploratory analyses were carried out to assess the potential differential association of the absolute and rHGS of the affected and non-affected with the above outcomes. All analyses were carried out using SPSS software (IBM SPSS Statistics for Windows, Version 27.0, IBM Corp., Armonk, New York, The United States). Statistical significance was set at $p < 0.05$.

| Variable                  | $n$ | Median | Mean | SD  | Minimum | Maximum |
|---------------------------|-----|--------|------|-----|---------|---------|
| Age (years)               | 60  | 53.2   | 52.3 | 9.0 | 28.8    | 70.2    |
| Height (cm)               | 60  | 160.0  | 160.1| 5.5 | 149.5   | 172.9   |
| Weight (kg)               | 60  | 67.4   | 68.7 | 11.5| 46.7    | 103.0   |
| BMI (kg/m²)               | 60  | 26.4   | 26.9 | 4.7 | 18.7    | 40.0    |
| Time since diagnosis (years) | 60  | 4.0    | 4.5  | 3.1 | 0.0     | 11.0    |
| HGS (kg)                  | 60  | 25.9   | 25.9 | 5.4 | 13.1    | 34.2    |

Table 1. Descriptive characteristics of the study participants.
### Table 1: Summary of Study Participants

| Variable                  | n  | %     |
|---------------------------|----|-------|
| rHGS (kg)                 | 60 | 1.9   |
| Arm volume difference (%) | 60 | 0.9   |
| DASH (range 0–100)        | 60 | 12.9  |
| DASH work (range 0–100)   | 58 | 0.0   |
| FACTI–F (range 0–52)      | 60 | 41.0  |
| CES–D (range 0–60)        | 60 | 13.5  |
| SWLS (range 0–25)         | 60 | 18.5  |
| EORTC QLQ-C30             |    |       |
| QL2 subscale (range 0–100)| 60 | 75.0  |
| PF2 subscale (range 0–100)| 60 | 93.3  |
| RF2 subscale (range 0–100)| 60 | 100.0 |
| EF subscale (range 0–100) | 60 | 75.0  |
| CF subscale (range 0–100) | 60 | 83.3  |
| SF subscale (range 0–100) | 60 | 83.3  |
| FA subscale (range 0–100) | 60 | 33.3  |
| NV subscale (range 0–100) | 60 | 0.0   |
| PA subscale (range 0–100) | 60 | 16.7  |
| DY subscale (range 0–100) | 60 | 0.0   |
| SL subscale (range 0–100) | 60 | 33.3  |
| AP subscale (range 0–100) | 60 | 0.0   |
| CO subscale (range 0–100) | 60 | 0.0   |
| DI subscale (range 0–100) | 60 | 0.0   |
| FI subscale (range 0–100) | 60 | 0.0   |
| EORTC QLQ-BR23            |    |       |
| ST subscale (range 0–100) | 60 | 21.4  |
| AS subscale (range 0–100) | 60 | 11.1  |
| BS subscale (range 0–100) | 60 | 8.3   |
| BI subscale (range 0–100) | 60 | 83.3  |
| FU subscale (range 0–100) | 60 | 66.7  |
| SEF subscale (range 0–100) | 60 | 33.3  |

**Variable**

- Affected arm
  - Left: 33 (55.0%)
  - Right: 26 (43.3%)
  - Both: 1 (1.7%)

- Tumor type (n = 60)
  - HR+/HER2−: 39 (65.1%)
  - HR+/HER2+: 11 (18.3%)
  - HR−/HER2+: 2 (3.3%)
  - HR−/HER2−: 8 (13.3%)

- Treatment (n = 60)
  - Chemotherapy: 46 (76.7%)
Radiotherapy 52 86.7
Surgical procedure (n = 60)
Tumorectomy 41 68.3
Mastectomy 18 30.0
No surgery 1 1.7
Lymph node resection (n = 60) 25 41.7
Endocrine therapy (n = 60) 52 86.7
Tamoxifen 34 56.7
Anastrozol 11 18.3
Paclitaxel 7 11.7
Trastuzumab 6 10.0
Goserelina 5 8.3
Letrozol 3 5.0
Exemestano 1 1.7

SD, standard deviation; HGS, handgrip strength; rHGS, relative handgrip strength; DASH, Disabilities of the Arm, Shoulder and Hand questionnaire; FACIT-F, Functional Assessment of Chronic Illness Therapy—Fatigue; CES-D, Center for Epidemiologic Studies Depression Scale; SWLS, Satisfaction with life scale; EORTC QLQ-C30, European Organization for Research and Treatment of Cancer; QL2, global health status/quality of life; PF2, physical function; RF2, task performance; EF, emotional performance; CF, cognitive performance; SF, social performance; FA, fatigue; NV, nausea and vomiting; PA, pain; DY, dyspnea; SL, insomnia; AP, loss of appetite; CO, constipation; DI, diarrhea; FI, financial difficulties; EORTC QLQ-BR23, European Organization for Research and Treatment of Cancer—breast cancer module; ST, side effects of therapy; AS, arm symptoms/discomfort; BS, breast symptoms/discomfort; BL, body image; FU, future perspective; SEF, sexual performance; RHI, hormone receptor; HER2, HER2 protein; BSGC, selective sentinel lymph node biopsy. *Difference between the volume of the right and left arm (expressed in %).

3. Results

The descriptive characteristics of the study participants are presented in Table 1. Sixty female breast cancer survivors with an average age of 52.3 years (standard deviation [SD] 9.0) participated in this study. A total of two women were unable to complete the body composition assessments using bioimpedance because of heart problems (the presence of pacemakers) and feet problems. The average time since diagnosis was 4.5 (SD 3.1) years, with a maximum of 11 years since diagnosis, and the average HGS was 25.9 (SD 5.4) kg.

Table 2 shows the association between HGS and rHGS to arms volume difference and self-reported shoulder–arm disabilities, fatigue, depressive symptoms, life satisfaction and HRQoL, adjusting for the participants’ age, BMI and time since diagnosis. A negative association was found between HGS and rHGS to shoulder–arm disabilities (assessed using both the DASH questionnaire and the arm symptoms/discomfort subscale of the EORTC QLQ-BR23 module). Additionally, a positive association between HGS and rHGS to global health status/quality of life subscale of the EORTC QLQ-C30 questionnaire was found. Furthermore, a significant negative association was found between HGS and rHGS to fatigue (assessed using both FACIT-F questionnaire and the fatigue subscale of the EORTC QLQ-C30 questionnaire). There was no association of absolute or relative HGS with depressive symptoms, life satisfaction or any other quality of life subscale of the EORTC QLQ-C30 and EORTC QLQ-BR23 questionnaires (all p > 0.05).
Table 2. Partial correlation assessing the association of HGS, and rHGS with arms volume difference, shoulder–arm disabilities, fatigue, depressive symptoms, life satisfaction and self-reported HRQoL in female breast cancer survivors.

| Variable          | HGS  | r     | p    | r     | p    |
|-------------------|------|-------|------|-------|------|
| Arms volume difference | -0.103 | 0.447 | -0.073 | 0.589 |
| DASH              | -0.210 | 0.123 | -0.418 | 0.001 |
| DASH work module  | -0.284 | 0.035 | -0.361 | 0.006 |
| FACIT-F           | 0.401  | 0.002 | 0.493  | <0.001 |
| CES-D            | -0.122 | 0.376 | -0.186 | 0.161 |
| SWLS             | 0.069  | 0.617 | 0.099  | 0.459 |
| EORTC QLQ-C30    |       |       |       |       |
| QL2 subscale     | 0.289  | 0.030 | 0.387  | 0.003 |
| PF2 subscale     | 0.103  | 0.448 | 0.254  | 0.054 |
| RF2 subscale     | 0.111  | 0.410 | 0.182  | 0.172 |
| EF subscale      | 0.211  | 0.115 | 0.179  | 0.179 |
| CF subscale      | 0.148  | 0.270 | 0.165  | 0.216 |
| SF subscale      | -0.093 | 0.491 | 0.188  | 0.157 |
| FA subscale      | -0.164 | 0.224 | -0.274 | 0.038 |
| NV subscale      | -0.041 | 0.764 | 0.121  | 0.365 |
| PA subscale      | -0.152 | 0.258 | -0.165 | 0.216 |
| DY subscale      | -0.005 | 0.972 | -0.052 | 0.698 |
| SL subscale      | -0.030 | 0.826 | -0.076 | 0.572 |
| AP subscale      | -0.246 | 0.065 | -0.100 | 0.457 |
| CO subscale      | -0.100 | 0.458 | 0.023  | 0.862 |
| DI subscale      | 0.014  | 0.920 | 0.067  | 0.619 |
| FI subscale      | 0.167  | 0.215 | -0.085 | 0.524 |
| EORTC QLQ-BR23   |       |       |       |       |
| ST subscale      | -0.139 | 0.304 | -0.140 | 0.294 |
| AS subscale      | -0.346 | 0.008 | -0.332 | 0.011 |
| BS subscale      | -0.025 | 0.856 | -0.108 | 0.421 |
| BI subscale      | 0.089  | 0.510 | 0.238  | 0.072 |
| FU subscale      | 0.153  | 0.256 | 0.120  | 0.370 |
| SEF subscale     | 0.078  | 0.565 | 0.197  | 0.138 |

r, partial correlation coefficient; p, p-value; DASH, Disabilities of the Arm, Shoulder and Hand questionnaire; FACIT-F, Functional Assessment of Chronic Illness Therapy-Fatigue; CES-D, Center for Epidemiologic Studies Depression Scale; SWLS, Satisfaction with life scale; EORTC QLQ-C30, European Organization for Research and Treatment of Cancer; QL2, global health status/quality of life; PF2, physical function; RF2, task performance; EF, emotional performance; CF, cognitive performance; SF, social performance; FA, fatigue; NV, nausea and vomiting; PA, pain; DY, dyspnea; SL, insomnia; AP, loss of appetite; CO, constipation; DI, diarrhea; FI, financial difficulties; EORTC QLQ-BR23, European Organization for Research and Treatment of Cancer—breast cancer module; ST, side effects of therapy; AS, arm symptoms/discomfort; BS, breast symptoms/discomfort; BI, body image; FU, future perspective; SEF, sexual performance. The analyses were adjusted for age, BMI, and time since diagnosis. *Difference between the volume of the right and left arm (expressed in %).

Table 3 shows the results of the linear regression analysis assessing the association between HGS and rHGS to the variables that were previously significant in the partial correlation analysis, controlling for the potential confounding effects of age, BMI and time elapsed since diagnosis. As examples, an additional kg in the HGS test was associated with 0.653 (95% CI 0.262 to 1.044; β = 0.397; p = 0.001) more units on the cancer-related fatigue scale, or with 1.114 (CI 95% 0.115 to 2.113; β = 0.289; p = 0.030) more units on the global health status/quality of life subscale of the EORTC QLQ-C30 questionnaire. Along the same lines, an additional kg of rHGS was associated with 12.589 (95% CI −19.914 to −5.265; β = −0.445; p = 0.001) units less on the disabilities of the arm, shoulder and hand.
scale, with 7.911 (95% CI 4.176 to 11.645; \( \beta = 0.515; p < 0.001 \)) more units on the cancer-related fatigue scale, or with 14.650 (95% CI 5.296 to 24.003; \( \beta = 0.408; p = 0.003 \)) units on the global health status/quality of life subscale of the EORTC QLQ-C30 questionnaire.

Table 3. Linear regression analysis assessing the association between HGS and rHGS to shoulder–arm disabilities, fatigue and HRQoL, controlling for the potential confounding effects of age, BMI and time elapsed since diagnosis.

| Variable               | HGS         | rHGS       |          |          |          |          |          |          |          |
|------------------------|-------------|------------|----------|----------|----------|----------|----------|----------|----------|
|                        | \( \beta \) | B          | SD       | 95% CI   | \( p \)  | \( \beta \) | B          | SD       | 95% CI   | \( p \)  |
| Weight                 | -0.040      | -0.085     | 0.290    | -0.666   | 0.496    | -0.771    | -0.591   | 11.722   | 2.301    | -16.331  | <0.001   |
| DASH                   | -0.244      | -0.740     | 0.382    | -1.507   | 0.026    | 0.058     | -0.445   | -12.589  | 3.656    | -19.914  | 0.001    |
| DASH work module       | -0.278      | -1.311     | 0.607    | -2.529   | -0.093   | 0.035     | -0.374   | -16.349  | 5.750    | -27.878  | <0.006   |
| FACTIT-F               | 0.397       | 0.653      | 0.195    | 0.262    | 1.044    | 0.001     | 0.515    | 7.911    | 1.864    | 4.176    | 0.001    |
| EORC QLQ-C30           | 0.289       | 1.114      | 0.499    | 0.115    | 2.113    | 0.030     | 0.408    | 14.650   | 4.669    | 5.296    | 0.003    |
| QL2 subscale           | -0.225      | -0.967     | 0.552    | -2.074   | 0.140    | 0.085     | -0.382   | -15.407  | 5.243    | -25.913  | 0.005    |
| FA subscale            | -0.347      | -1.300     | 0.476    | -2.253   | -0.346   | 0.008     | -0.343   | -11.993  | 4.546    | -21.100  | 0.011    |

\( \beta \), standardized regression coefficient; B, non-standardized regression coefficient; SD, standard deviation; CI, confidence interval; \( p \), \( p \)-value; BMI, body mass index; HGS, hand grip strength; DASH, Disabilities of the Arm, Shoulder and Hand questionnaire; FACTIT-F, Functional Assessment of Chronic Illness Therapy-Fatigue; EORC QLQ-C30, European Organization for Research and Treatment of Cancer; QL2, global health status/quality of life; EORC QLQ-BR23, European Organization for Research and Treatment of Cancer—breast cancer module; AS, arm symptoms/discomfort. The analyses were adjusted for age, BMI (body mass index) and time since diagnosis, except for the body composition variables, where BMI was excluded as the adjustment variable.

The exploratory analyses assessing the specific associations of HGS and rHGS, differentially assessed with the affected and nonaffected arms, with all the outcomes are presented in Appendix A (Table A1). Overall, the association of the absolute and relative HGS of both arms showed a similar association with the outcomes.

4. Discussion

The main findings of the present study suggest that a higher absolute HGS is associated with fewer shoulder–arm disability, less cancer-related fatigue and greater HRQoL in female breast cancer survivors. Furthermore, a higher rHGS is significantly associated with less shoulder-arm disabilities, less cancer-related fatigue and higher HRQoL. These results suggest that both absolute and relative HGS may be good indicators of the health status of breast cancer survivors in the follow-up after core treatments. Particularly, the rHGS revealed relatively stronger associations with the studied outcomes.

No association of HGS, or rHGS with arms volume difference was observed. However, the present study observed a negative association of HGS and rHGS with shoulder–arm impairments. In this line, other studies [38,70], observed that higher HGS was associated with lower upper limb disability. Additionally, Lee et al. [38], observed a negative association of HGS with subjective weakness of the affected arm, fear of using the affected arm, and recommendations from the medical professional to restrict the use of the affected arm and with limited activity in the affected arm. Future research should elucidate if upper limb impairments and limited physical activity might be associated to medical recommendations, which would highlight the great influence of medical support in the follow-up after completing breast cancer treatments, specifically, on shoulder–arm disability.

The negative associations observed between HGS and rHGS with cancer-related fatigue, support the findings obtained by Kalter et al. [43], Kneis et al. [44], and Cantarero-Villanueva et al. [52], who observed that higher HGS was associated with lower cancer-related fatigue. Fatigue is one of the main side effects related to breast cancer treatments [6] and its significant increase during and after treatments cause a decrease in the patients’ quality of life, as well as in their ability to carry out daily life activities [71]. Then,
considering the impact that fatigue may have on breast cancer survivors’ lives, assessing its presence becomes of major importance and absolute and relative HGS test may be very useful tools.

Despite what has been indicated in the previous literature [39,40,42,52], no association was observed between HGS, or rHGS, with depressive symptoms. This may be due to the use of different assessment instruments.

It has been shown that HRQoL is reduced after breast cancer core treatments [16]. The results presented in this study suggest that higher HGS and rHGS are associated with higher self-reported quality of life. These results are in line with those of Kaya et al. [41], and Paek and Choi [42], who observed that lower HGS was associated with lower HRQoL, in spite of using different HRQoL scales. Further prospective research is needed to elucidate whether absolute or relative HGS might be associated with a lower decrease of HRQoL in the follow-up (e.g., 10 years as the context of this study) after completing the core treatments for breast cancer.

It should be noted that additional exploratory analyses were carried out to determine if HGS or rHGS of the affected and nonaffected arms could show stronger associations with the different self-reported physical function and quality of life studied outcomes, but the observed results were similar to previous analyses. Other studies analyzed the association of HGS of the affected arm [40,44,52] and HGS of the dominant hand [43,53] with physical function and HRQoL outcomes but any of them explored if using HGS of the affected and nonaffected arm or both could show stronger associations.

The handgrip strength test is a quick, simple and economically feasible assessment that may help clinicians initiate a process to identify the presence of shoulder–arm disabilities and cancer-related fatigue, as well as a decrease of quality of life in breast cancer survivors, which constitute three of the main side effects during and after cancer treatments. The detection of these side effects could lead to the implementation of actions for their improvement, causing a significant improvement on these patients’ well-being.

To the best of our knowledge, the present study is the first to examine the association of rHGS with different self-reported physical function and quality of life outcomes. According to these results, rHGS shows relatively stronger associations than HGS with all the analyzed outcomes. Consequently, rHGS could be speculated to be a better potential predictor of physical function and HRQoL.

This study also included standardized assessment instruments for this population, which has shown relevant associations that may contribute to the inclusion of HGS assessment in clinical practice, facilitating the early detection of breast cancer treatments side effects, and their improvement. However, further prospective research is needed to evaluate the utility of implementing the handgrip strength test in clinical practice to predict the deterioration of function and patient-reported outcomes following treatments.

This study has limitations that must be highlighted. The cross-sectional design precludes the establishment of causal relationships. The sample size was relatively low and studies with larger samples are needed to confirm or contrast these findings. Additionally, women included in the study had undergone breast cancer surgery and finished the core treatments up to 10 years before enrolment, which might result in a rather heterogeneous sample. Finally, we lacked information on the history of hormone therapy, which could affect muscle quality and strength.

5. Conclusions

In conclusion, the results of the present study suggest that both HGS and, particularly, rHGS could be good indicators of shoulder–arm disabilities, fatigue and decreased quality of life in breast cancer survivors.

**Author Contributions:** Conceptualization, A.E.-S., M.A.R.-P., A.J.C.-A. and A.S.-M.; data curation, A.E.-S., D.M.D.-F., E.A.-R., M.A.C.-A., H.M.-M., M.A.R.-P., A.J.C.-A. and A.S.-M.; formal analysis, A.E.-S., E.A.-R., M.A.C.-A. and A.S.-M.; funding acquisition, A.J.C.-A. and A.S.-M.; investigation,
A.E.-S., D.M.D.-F., E.A.-R., M.Á.C.-A., H.M.-M., M.A.R.-P., A.J.C.-A. and A.S.-M.; methodology, A.E.-S., E.A.-R., M.Á.C.-A. and A.S.-M.; project administration, A.J.C.-A. and A.S.-M.; resources, H.M.-M., A.J.C.-A. and A.S.-M.; software, A.E.-S., D.M.D.-F., E.A.-R., M.Á.C.-A. and A.S.-M.; supervision, A.J.C.-A. and A.S.-M.; validation, E.A.-R. and M.Á.C.-A.; visualization, A.E.-S., D.M.D.-F., E.A.-R., M.Á.C.-A., H.M.-M., M.A.R.-P., A.J.C.-A. and A.S.-M.; writing—original draft, A.E.-S., D.M.D.-F. and A.S.-M.; writing—review and editing, A.E.-S., D.M.D.-F., E.A.-R., M.Á.C.-A., H.M.-M., M.A.R.-P., A.J.C.-A. and A.S.-M. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by the Patronato Municipal de Deportes, Ayuntamiento de Almería, and by the UAL Transfiriere Research Program [reference number: TRFE-SI-2019/004]. DMD-F was funded by a scholarship from the UAL Transfiriere Research Program of the University of Almería [reference number: TRFE-BT-2019/002] and is currently funded by the Ministry of Science, Innovation and Universities of the government of Spain (grant number: FPU19/04608). Alberto Soriano-Maldonado was supported by the Spanish Ministry of Science, Innovation and Universities (ref. RTI2018-093302-A-I00).

**Institutional Review Board Statement:** The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Ethics Committee of the Hospital Universitario Torrecárdenas de Almeria, Spain (ref: Ejercicio-CáncerUAL [9 8/2019]).

**Informed Consent Statement:** Informed consent was obtained from all subjects involved in the study.

**Data Availability Statement:** The data presented in this study are available on reasonable request and for research purposes from the corresponding author.

**Acknowledgments:** The authors would like to thank the associations of patients that have provided support to the project, including “Asociación Proyecto Mariposa”, “Asociación Española Contra el Cáncer”, and “Asociación Amam Almería”.

**Conflicts of Interest:** The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

### Appendix A

**Table A1.** Partial correlation assessing the association of HGS, and rHGS of the affected and nonaffected arms with arms volume difference, shoulder-arm disabilities, fatigue, depressive symptoms, life satisfaction and self-reported HRQoL in female survivors of breast cancer.

| Variable                  | HGS Affected arm | HGS Nonaffected arm | rHGS Affected arm | rHGS Nonaffected arm |
|---------------------------|------------------|---------------------|------------------|---------------------|
| n                         |                  |                     |                  |                     |
| Arms volume difference a  | 60               | -0.083              | 0.554            | -0.069              | 0.621              | -0.107              | 0.444              | -0.099              | 0.477              |
| DASH                      | 60               | -0.255              | 0.066            | -0.437              | 0.001              | -0.127              | 0.363              | -0.339              | 0.012              |
| DASH work module          | 58               | -0.346              | 0.011            | -0.433              | 0.001              | -0.211              | 0.129              | -0.331              | 0.015              |
| FACIT-F                   | 60               | 0.373               | 0.006            | 0.490               | <0.001             | 0.433               | 0.001              | 0.527               | <0.001             |
| CES-D                     | 60               | -0.069              | 0.622            | -0.135              | 0.329              | -0.137              | 0.330              | -0.198              | 0.152              |
| SWLS                      | 60               | -0.040              | 0.775            | 0.023               | 0.870              | 0.142               | 0.310              | 0.158               | 0.253              |
| EORTC QLQ-C30             |                  |                     |                  |                     |                   |                     |                   |                     |                   |
| QL2 subscale              | 60               | 0.188               | 0.177            | 0.319               | 0.019              | 0.267               | 0.053              | 0.387               | 0.004              |
| PF2 subscale              | 60               | 0.085               | 0.546            | 0.332               | 0.014              | 0.076               | 0.590              | 0.320               | 0.018              |
| RF2 subscale              | 60               | 0.132               | 0.347            | 0.306               | 0.024              | -0.020              | 0.889              | 0.196               | 0.156              |
| EF subscale               | 60               | 0.228               | 0.101            | 0.220               | 0.110              | 0.247               | 0.075              | 0.236               | 0.086              |
| CF subscale               | 60               | 0.151               | 0.282            | 0.193               | 0.163              | 0.119               | 0.398              | 0.185               | 0.181              |
SF subscale 60 −0.134 0.338 0.215 0.119 −0.105 0.454 0.236 0.085
FA subscale 60 −0.131 0.352 −0.332 0.014 −0.150 0.284 −0.341 0.011
NV subscale 60 −0.169 0.227 −0.017 0.902 −0.186 0.181 −0.115 0.406
PA subscale 60 −0.105 0.454 −0.220 0.109 −0.039 0.780 −0.176 0.202
DY subscale 60 0.010 0.943 −0.108 0.437 0.070 0.616 −0.064 0.646
SL subscale 60 −0.041 0.768 −0.112 0.422 0.031 0.826 −0.077 0.582
AP subscale 60 −0.360 0.008 −0.311 0.022 −0.157 0.262 −0.171 0.216
CO subscale 60 −0.045 0.747 0.040 0.772 −0.073 0.604 0.022 0.876
DI subscale 60 −0.018 0.897 0.008 0.954 −0.123 0.381 −0.079 0.569
FI subscale 60 0.115 0.411 −0.157 0.256 0.171 0.222 −0.124 0.372
EORTC QLQ-BR23
ST subscale 60 −0.159 0.255 −0.181 0.191 −0.076 0.591 −0.133 0.337
AS subscale 60 −0.344 0.012 −0.339 0.012 −0.229 0.099 −0.249 0.070
BS subscale 60 −0.002 0.990 −0.097 0.487 0.039 0.779 −0.060 0.664
BI subscale 60 0.069 0.625 0.241 0.079 0.193 0.167 0.326 0.016
FU subscale 60 0.207 0.137 0.139 0.316 0.045 0.750 0.024 0.864
SEF subscale 60 0.012 0.934 0.162 0.242 0.095 0.497 0.208 0.130

r, correlation coefficient; p, p-value; DASH, Disabilities of the Arm, Shoulder and Hand questionnaire; FACIT-F, Functional Assessment of Chronic Illness Therapy-Fatigue; CES-D, Center for Epidemiologic Studies Depression Scale; SWLS, Satisfaction with life scale; EORTC QLQ-C30, European Organization for Research and Treatment of Cancer; QL2, global health status/quality of life; PF2, physical function; RF2, task performance; EF, emotional performance; CF, cognitive performance; SF, social performance; FA, fatigue; NV, nausea and vomiting; PA, pain; DY, dyspnea; SL, insomnia; AP, loss of appetite; CO, constipation; DI, diarrhea; FI, financial difficulties; EORTC QLQ-BR23, European Organization for Research and Treatment of Cancer—breast cancer module; ST, side effects of therapy; AS, arm symptoms/discomfort; BS, breast symptoms/discomfort; BI, body image; FU, future perspective; SEF, sexual performance. The analyses were adjusted for age, BMI, and time since diagnosis. △Difference between the volume of the right and left arm (expressed in %).

References
1. World Health Organisation. Global Cancer Observatory. Globocan. Cancer Today. 2020. Available online: https://www.uicc.org/news/globocan (accessed on 30 March 2021).
2. Asociación Española Contra el Cáncer (AECC). Datos de Cáncer de mama en 2019. Available online: https://www.aecc.es/es/todo‐cancer/cancer‐mama (accessed on 30 March 2021).
3. Sociedad Española de Oncología Médica (SEOM). Las Cifras del Cáncer en España en 2021. Available online: https://seom.org/images/Cifras_del_cancer_en_Espana_2021.pdf (accessed on 30 March 2021).
4. Campbell, K.L.; Neil, S.E.; Winter‐Stone, K.M. Review of exercise studies in breast cancer survivors: Attention to principles of exercise training. Br. J. Sports Med. 2012, 46, 909‐916.
5. Rockson, S.G. Lymphedema after Breast Cancer Treatment. N. Engl. J. Med. 2018, 379, 1937–1944.
6. Stasi, R.; Abriani, L.; Beccaglia, P.; Terzoli, E.; Amadori, S. Cancer‐related fatigue: Evolving concepts in evaluation and treatment. Cancer 2003, 98, 1786–1801.
7. Hidding, J.T.; Beurskens, C.H.; van der Wees, P.J.; van Laarhoven, H.W.; Nijhuis‐van der Sanden, M.W. Treatment related impairments in arm and shoulder in patients with breast cancer: A systematic review. PLoS ONE 2014, 9, e96748.
8. Hayes, S.C.; Johansson, K.; Stout, N.L.; Prosnitz, R.; Armer, J.M.; Gabram, S.; Schmitz, K.H. Upper‐body morbidity after breast cancer: Incidence and evidence for evaluation, prevention, and management within a prospective surveillance model of care. Cancer 2012, 118, 2237–2249.
9. Peel, A.B.; Thomas, S.M.; Dittus, K.; Jones, L.W.; Lakoski, S.G. Cardiorespiratory fitness in breast cancer patients: A call for normative values. J. Am. Heart Assoc. 2014, 3, e000432.
10. Jones, L.W.; Courneya, K.S.; Mackey, J.R.; Muss, H.B.; Pituskin, E.N.; Scott, J.M.; Hornsby, W.E.; Coan, A.D.; Herdon, J.E.; Douglas, P.S.; et al. Cardiopulmonary function and age‐related decline across the breast cancer survivorship continuum. J. Clin. Oncol. 2012, 30, 2530–2537.
11. Bruera, E.; Brenneis, C.; Michaud, M.; Jackson, P.I.; MacDonald, R.N. Muscle electrophysiology in patients with advanced breast cancer. J. Natl. Cancer Inst. 1988, 80, 282–285.
12. Vainshelboim, B.; Müller, J.; Lima, R.M.; Nead, K.T.; Chester, C.; Chan, K.; Kokkinos, P.; Myers, J. Cardiorespiratory fitness, physical activity and cancer mortality in men. *Prev. Med. 2017*, **100**, 89–94.

13. Villaseñor, A.; Ballard-Barbash, R.; Baumgartner, K.; Baumgartner, R.; Bernstein, L.; McTiernan, A.; Neuhaus, M.L. Prevalence and prognostic effect of sarcopenia in breast cancer survivors: The HEAL Study. *J. Cancer Surviv. 2012*, **6**, 398–406.

14. Yeboa, D.N.; Evans, S.B. Contemporary Breast Radiotherapy and Cardiac Toxicity. *Semin. Radiat. Oncol. 2016*, **26**, 71–78.

15. Spiegel, D.; Giese-Davis, J. Depression and Cancer: Mechanisms and Disease Progression. *Biol. Psychiatry 2003*, **54**, 269–282.

16. Mols, F.; Vingerhoets, A.J.; Coebergh, J.W.; van de Poll-Fранce, L.V. Quality of life among long-term breast cancer survivors: A systematic review. *J. Strength Cond. Res. 2005*, **29**, 2656–2665.

17. Burns, R.D.; Brusseau, T.A. Muscular strength and endurance and cardio-metabolic health in disadvantaged Hispanic children from the U.S. *Prev. Med. Rep. 2017*, **5**, 21–26.

18. Henriksson, H.; Henriksson, P.; Tynelius, P.; Ekstedt, M.; Berglind, D.; Labayen, I.; Ruiz, J.R.; Lavie, C.J.; Ortega, F.B. Cardiorespiratory fitness, muscular strength, and obesity in adolescence and later chronic disability due to cardiovascular disease: A cohort study of 1 million men. *Eur. Heart J. 2020*, **41**, 1503–1510.

19. Kujala, U.M.; Vaara, J.P.; Kainulainen, H.; Vasankari, T.; Vaara, E.; Kyröläinen, H. Associations of aerobic fitness and maximal muscular strength with metabolites in young men. *JAMA Netw. Open 2019*, **2**, e198265.

20. Tarp, J.; Stele, A.P.; Blond, K.; Grantved, A. Cardiorespiratory fitness, muscular strength and risk of type 2 diabetes: A systematic review and meta-analysis. *Diabetologia 2019*, **62**, 1129–1142.

21. Chan, O.Y.A.; van Houwelingen, A.H.; Gusselkoo, J.; Blom, J.W.; den Elzen, W.P.J. Comparison of quadriceps strength and handgrip strength in their association with health outcomes in older adults in primary care. *Age (Doradt) 2014*, **36**, 9714.

22. Yang, J.; Christphi, C.A.; Farioli, A.; Baur, D.M.; Moffatt, S.; Zollinger, T.W.; Kales, S.N. Association Between Push-up Exercise Capacity and future Cardiovascular Events Among Active Adult Men. *JAMA Netw. Open 2019*, **2**, e188341.

23. Levinger, I.; Scott, D.; Nicholson, G.C.; Stuart, A.L.; Duque, G.; McCorquodale, T.; Herrmann, M.; Ebeling, P.R.; Sanders, K.M. Undercarboxylated osteocalcin, muscle strength and indices of bone health in older women. *Bone 2014*, **64**, 8–12.

24. Ruiz, J.R.; Sui, X.; Lobelo, F.; Morrow, J.R.; Jackson, A.W.; Sjöström, M.; Blair, S.N. Association between muscular strength and mortality in men: Prospective cohort study. *BMJ (Online) 2008*, **337**, a439.

25. Fabs, C.A.; Thiebaud, R.S.; Rossow, L.M.; Loenneke, J.P.; Bemben, D.A.; Bemben, M.G. Relationship between central arterial stiffness, lean body mass, and absolute and relative strength in young and older men and women. *Clin. Physiol. Funt. Imaging 2018*, **38**, 676–680.

26. Hart, P.D. Grip Strength and Health-Related Quality of Life in U.S. Adult Males. *J. Lifestyle Med. 2019*, **9**, 102–110.

27. Bohannon, R.W. Hand-grip dynamometry predicts future outcomes in aging adults. *J. Geriatr. Phys. Ther. 2008*, **31**, 3–10.

28. Sola-Rodriguez, S.; Vargas-Hitos, J.A.; Gavilán-Carrera, B.; Rosales-Castillo, A.; Sabio, J.M.; Hernández-Martínez, A.; Martínez-Rosales, E.; Ortego-Centeno, N.; Soriano-Maldonado, A. Relative Handgrip Strength as Marker of Cardiometabolic Risk in Women with Systemic Lupus Erythematosus. *Int. J. Environ. Res. Public Health 2021*, **18**, 4630.

29. Semperé-Rubio, N.; Aguilar-Rodriguez, M.; Inglés, M.; Izquierdo-Alventosa, R.; Serra-Añó, R. Physical Condition Factors that Predict a Better Quality of Life in Women with Fibromyalgia. *Int. J. Environ. Res. Public Health 2019*, **16**, 3173.

30. Ramirez-Vélez, R.; Peña-Ibagón, J.C.; Martinez-Torres, J.; Tordecilla-Sanders, A.; Correa-Bautista, J.E.; Lobelo, F.; García-Hermoso, A. Handgrip strength index for cardiometabolic risk index among Colombian children and adolescents: The FUPRECOL Study. *Sci. Rep. 2017*, **7**, 42622.

31. Lee, W.; Peng, L.; Chiu, S.; Chen, L. Relative Handgrip Strength is a Simple Indicator of Cardiometabolic Risk among Middle-Aged and Older People: A Nationwide Population-Based Study in Taiwan. *PLoS ONE 2016*, **11**, e0160876.

32. Lawman, H.G.; Troiano, R.P.; Perma, F.M.; Wang, C.; Fryar, C.D.; Ogden, C.L. Associations of Relative Handgrip Strength and Cardiovascular Disease Biomarkers in U.S. Adults, 2011-2012. *Am. J. Prev. Med. 2015*, **50**, 677–683.

33. Yates, T.; Zaccardi, F.; Dhalwani, N.N.; Davies, M.J.; Bakrania, K.; Celis-Morales, C.A.; Gill, J.M.R.; Franks, P.W.; Khunti, K. Association of walking pace and handgrip strength with all-cause, cardiovascular, and cancer mortality. *A UK Biobank observational study*.

34. Leong, D.P.; Teo, K.K.; Rangarajan, S.; López-Jaramillo, P.; Avezum, A.; Orlandini, A.; Seron, P.; Ahmed, S.H.; Rosengren, A.; Kelishadi, R.; et al. Prognostic value of grip strength: Findings from the Prospective Urban Rural Epidemiology (PURE) study. *Lancet 2015*, **386**, 266–273.

35. Bohannon, R.W. Dynamometer measurements of hand-grip strength predict multiple outcomes. *Percept. Mot. Skills 2001*, **93**, 323–328.

36. García-Hermoso, A.; Ramírez-Vélez, R.; Peterson, M.D.; Lobelo, F.; Cavero-Redondo, I.; Correa-Bautista, J.E.; Martínez-Vizcaino, V. Handgrip and knee extension strength as predictors of cancer mortality: A systematic review and meta-analysis. *Scand. J. Med. Sci. Sports 2018*, **28**, 1852–1858.

37. Beaton, D.E.; Katz, J.N.; Fossel, A.H.; Wright, J.G.; Tarasuk, V.; Bombardier, C. Measuring the whole or the parts? Validity, reliability, and responsiveness of the Disabilities of the Arm, Shoulder and Hand outcome measure in different regions of the upper extremity. *J. Hand Ther. 2001*, **14**, 128–146.

38. Lee, D.; Hwang, J.H.; Chu, I.; Chang, H.J.; Hun Shim, Y.; Kim, J.H. Analysis of factors related to arm weakness in patients with breast cancer-related lymphedema. *Support Care Cancer 2015*, **23**, 2297–2304.
39. Lee, M.; Jung, S.M.; Bang, H.; Kim, H.S.; Kim, Y.B. The association between muscular strength and depression in Korean adults: A cross-sectional analysis of the sixth Korea National Health and Nutrition Examination Survey (KNHANES VI) 2014. BMC Public Health 2018, 18, 1123.
40. Galiano-Castillo, N.; Ariza-García, A.; Cantarero-Villanueva, I.; Fernández-Lao, C.; Díaz-Rodríguez, L.; Arroyo-Morales, M. Depressed mode in breast cancer survivors: Associations with physical activity, cancer-related fatigue, quality of life, and fitness level. Eur. J. Oncol. Nurs. 2014, 18, 206–210.
41. Kaya, T.; Karatepe, A.G.; Güneydın, R.; Yetis, H.; Uslu, A. Disability and Health-Related Quality of Life After Breast Cancer Surgery: Relation to Impairments. South. Med. J. 2010, 103, 37–41.
42. Paek, J.; Choi, Y.J. Association between hand grip strength and impaired health-related quality of life in Korean cancer survivors: A cross-sectional study. BMJ Open 2019, 9, e030938.
43. Kalter, J.; Kampshoff, C.S.; Chinapan, M.J.M.; van Mechelen, W.; Galindo-Garre, F.; Schep, G.; Verdonck-de Leeuw, I.M.; Brug, J.; Buffart, L.M. Mediators of exercise effects on health-related quality of life in cancer survivors after chemotherapy. Med. Sci. Sports Exerc. 2016, 48, 56–69.
44. Kneis, S.; Wehrle, A.; Iaender, A.; Volegová-Neher, N.; Gollhofer, A.; Bertz, H. Results from a Pilot Study of Handheld Vibrations: Exercise Intervention Reduces Upper-Limb Dysfunction and Fatigue in Breast Cancer Patients Undergoing Radiotherapy: VibBra Study. Int. J. Cancer Ther. 2018, 17, 717–727.
45. Esteban-Simón, A.; Diez-Fernández, D.M.; Alcaraz-García, C.; García-Martínez, M.M.; Moreno-Pozo, N.; Maldonado-Quesada, M.; Carrera-Ruiz, A.; Toro-de-Federico, A.; Hachem-Salas, N.; Moreno-Martos, H.; et al. ¿Es la fuerza de presión manual un buen indicador de condición física y composición corporal en pacientes con cáncer de mama que han terminado los tratamientos centrales de la enfermedad? Estudio EFICAN. Rev. Andal. De Med. Del Deporte 2021, 14, 131–136.
46. Choquette, S.; Bouchard, D.R.; Doyon, C.Y.; Sénéchal, M.; Brochu, M.; Dionne, I.J. Relative strength as a determinant of mobility in elders 67-84 years of age. A nuage study: Nutrition as a determinant of successful aging. J. Nutr. Health Aging 2010, 14, 190–195.
47. Souza, W.; Prestes, J.; Schwerz, S.; Navalta, J.W.; Tibana, R.A.; da Cunha, D. Relation Between Relative Handgrip Strength, Chronological Age and Physiological Age with Lower Functional Capacity in Older Women. Open Access J. Sports Med. 2019, 10, 185–190.
48. Silva, C.R.; Saraiva, B.; da Cunha, D.; Oliveira, S.C.; Sousa, I.; Valduga, R.; Santos, N.G.; Tibana, R.A.; Prestes, J.; Willardson, J.M.; et al. Relative Handgrip Strength as a Simple Tool to Evaluate Impaired Heart Rate Recovery and a Low chronotropic Index in Obese Older Women. Int. J. Exerc. Sci. 2018, 11, 844–855.
49. Ji, C.; Xia, Y.; Tong, S.; Wu, Q.; Zhao, Y. Association of handgrip strength with the prevalence of metabolic syndrome in US adults: The national health and nutrition examination survey. Aging (Albany NY) 2020, 12, 7818–7829.
50. Ahn, K.; Lee, T.; Sohn, T.; Kim, D.Y.; Ryu, M.; Gym, H.; Lee, S. Association between Relative Handgrip Strength and Osteoporosis in Older Women: The Korea National Health and Nutrition Examination Survey 2014–2018. Ann. Geriatr. Med. Res. 2020, 24, 243–251.
51. Soriano-Maldonado, A.; Carrera-Ruiz, A.; Diez-Fernández, D.M.; Esteban-Simón, A.; Maldonado-Quesada, M.; Moreno-Pozo, N.; García-Martínez, M.D.M.; Alcaraz-García, C.; Vázquez-Sousa, R.; Moreno-Martos, H.; Toro-de-Federico, A.; et al. Effects of a 12-week resistance and aerobic exercise program on muscular strength and quality of life in breast cancer survivors: Study protocol for the EFICAN randomized controlled trial. Medicine 2019, 98, e7625.
52. Cantarero-Villanueva, I.; Fernández-Lao, C.; Díaz-Rodríguez, L.; Fernández-de-las-Peñas, C.; Ruiz, J.R.; Arroyo-Morales, M. The Handgrip Strength Test as a Measure of Function in Breast Cancer Survivors. Relationship to cancer-related symptoms and physical and psychological parameters. Am. J. Phys. Med. Rehabil. 2012, 91, 774–782.
53. Yee, J.; Davis, G.M.; Beith, J.M.; Willeken, N.; Curow, D.; Emery, J.; Philips, J.; Martin, A.; Hui, R.; Harrison, M.; et al. Physical activity and fitness in women with metastatic breast cancer. J. Cancer Surviv. 2014, 8, 647–656.
54. Harrington, S.; Padua, D.; Battaglini, C.; Michener, L.A. Upper extremity strength and range of motion and their relationship to function in breast cancer survivors. Physiother. Theory Pract. 2013, 29, 513–520.
55. Ruiz-Ruiz, J.; Mesa, J.L.; Gutiérrez, A.; Castillo, M.J. Hand size influences optimal grip span in women but not in men. J. Hand Surg. 2002, 27, 897–901.
56. Sander, A.; Hajer, N.M.; Hemenway, K.; Miller, A.C. Upper-Extremity Volume Measurements in Women with Lymphedema: A Comparison of Measurements Obtained Via Water Displacement with Geometrically Determined Volume. Phys. Ther. 2002, 82, 1201–1212.
57. Hervás, M.T.; Navarro, M.J.; Peiró, S.; Rodrigo, J.L.; López, P.; Martínez, I. Spanish version of the DASH questionnaire. Cross-cultural adaptation, reliability, validity and responsiveness. Med. Clin. 2006, 127, 441–447.
58. Dapueto, J.J.; Abreu, M.C.; Francolino, C.; Levin, R.J. Psychometric assessment of the MSAS-SF and the FACIT-Fatigue Scale in Spanish-speaking patients with cancer in Uruguay. J. Pain Symptom Manag. 2014, 47, 936–945.
59. Yellen, S.B.; Cellà, D.F.; Webster, K.; Blendowski, C.; Kaplan, E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J. Pain Symptom Manag. 1997, 13, 63–74.
60. González, V.M.; Stewart, A.; Ritter, P.L.; Lorig, K. Translation and validation of arthritis outcome measures into Spanish. Arthritis Rheum. 1995, 38, 1429–1446.
61. Radloff, L.S. The CES-D Scale. Appl. Psychol. Meas. 1977, 1, 385–401.
62. Diener, E.; Emmons, R.; Larsen, R.J.; Griffin, S. The Satisfaction with Life Scale. J. Personal. Assess. 1985, 49, 71–75.
63. Requena-Hernández, C.; López-Fernández, V.; González-Boto, R.; Ortiz-Alonso, T. Psychometric properties of the satisfaction with life scale in active elderly women. Rev. Española Geriatría Gerontol. 2009, 44, 146–148.
64. Lorenzo-Seva, U.; Calderón, C.; Ferrando, P.J.; Muñoz, M.M.; Beato, C.; Ghanem, I.; Castelo, B.; Carmona-Bayonas, A.; Hernández, R.; Jiménez-Fonseca, P. Psychometric properties and factorial analysis of invariance of the Satisfaction with Life Scale (SWLS) in cancer patients. Qual. Life Res. 2019, 28, 1255–1264.
65. Aaronson, N.K.; Ahmedzai, S.; Bergman, B.; Bullinger, M.; Cull, A.; Duez, N.J.; Filiberti, A.; Flechtner, H.; Fleishman, S.B.; de Haes, J.C.J.M.; et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology. J. Natl. Cancer Inst. 1993, 85, 365–376.
66. Arraras, J.I.; Garrido, E.; Pruja, E.; Marcos, M.; Tejedor, M.; Arias, F. El Cuestionario de Calidad de Vida de la EORTC QLQ-C30 (Versión 2.0). Estudio psicométrico con pacientes con cáncer de mama. Clinica Y Salud 2000, 11, 329–349.
67. Sprangers, M.A.; Groenvold, M.; Arraras, J.I.; Franklin, J.; de Velde, A.; Muller, M.; Franzini, L.; Williams, A.; de Haes, H.C.; Hopwood, P.; et al. The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: First results from a three-country field study. J. Clin. Oncol. 1996, 14, 2756–2768.
68. Arraras, J.I.; Tejedor, M.; Illarramendi, J.J.; Vera, R.; Pruja, E.; Marcos, M.; Arias, F.; Valerdi, J.J. El Cuestionario de Calidad de Vida para Cáncer de Mama de la EORTC, QLQ-BR: Estudio psicométrico con una muestra española. Psicol. Conduct. 2001, 9, 81–97.
69. Fayers, P.M.; Aaronson, N.K.; Bjordal, K.; Groenvold, M.; Curran, D.; Bottomley, A. The EORTC QLQ_C30 Scoring Manual, 3rd ed.; European Organisation for Research and Treatment of Cancer: Brussels, Belgium, 2001.
70. De Groef, A.; Meeus, M.; De Vrieze, T.; Vos, L.; Van Kampen, M.; Christiaens, M.R.; Neven, P.; Geraerts, I.; Devoogdt, N. Pain characteristics as important contributing factors to upper limb dysfunctions in breast cancer survivors at long term. Musculoskelet. Sci. Pract. 2017, 29, 52–59.
71. Hofman, M.; Ryan, J.L.; Figueroa-Moseley, C.D.; Jean-Pierre, P.; Morrow, G.R. Cancer-related fatigue: The scale of the problem. Oncologist 2007, 12, 4–10.